Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 202

1.

Mobilization of hematopoietic stem cells into the peripheral blood.

Damon LE, Damon LE.

Expert Rev Hematol. 2009 Dec;2(6):717-33. doi: 10.1586/ehm.09.54. Review.

PMID:
21082960
[PubMed - indexed for MEDLINE]
2.

Plerixafor: a peripheral blood stem cell mobilizer.

Kessans MR, Gatesman ML, Kockler DR.

Pharmacotherapy. 2010 May;30(5):485-92. doi: 10.1592/phco.30.5.485. Review.

PMID:
20411999
[PubMed - indexed for MEDLINE]
3.

Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.

Pusic I, DiPersio JF.

Curr Opin Hematol. 2010 Jul;17(4):319-26. doi: 10.1097/MOH.0b013e328338b7d5. Review.

PMID:
20473162
[PubMed - indexed for MEDLINE]
4.

FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.

Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee SL, Saber H, Fourie J, Tornoe C, Booth B, Yuan W, He K, Justice R, Pazdur R.

Oncology. 2010;78(3-4):282-8. doi: 10.1159/000315736. Epub 2010 Jun 8.

PMID:
20530974
[PubMed - indexed for MEDLINE]
5.

Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.

Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK.

Transfusion. 2011 Oct;51(10):2175-82. doi: 10.1111/j.1537-2995.2011.03136.x. Epub 2011 Apr 14.

PMID:
21492180
[PubMed - indexed for MEDLINE]
6.

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.

Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G.

Biol Blood Marrow Transplant. 2009 Feb;15(2):249-56. doi: 10.1016/j.bbmt.2008.11.028.

PMID:
19167685
[PubMed - indexed for MEDLINE]
7.

Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.

Russell N, Douglas K, Ho AD, Mohty M, Carlson K, Ossenkoppele GJ, Milone G, Pareja MO, Shaheen D, Willemsen A, Whitaker N, Chabannon C.

Haematologica. 2013 Feb;98(2):172-8. doi: 10.3324/haematol.2012.071456. Epub 2012 Sep 14.

PMID:
22983579
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.

Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED.

Pharmacotherapy. 2012 Jul;32(7):596-603. doi: 10.1002/j.1875-9114.2012.01096.x.

PMID:
22760691
[PubMed - indexed for MEDLINE]
9.

In and out of the niche: perspectives in mobilization of hematopoietic stem cells.

Mohty M, Ho AD.

Exp Hematol. 2011 Jul;39(7):723-9. doi: 10.1016/j.exphem.2011.05.004. Epub 2011 May 13. Review.

PMID:
21624427
[PubMed - indexed for MEDLINE]
10.

Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.

Steinberg M, Silva M.

Clin Ther. 2010 May;32(5):821-43. doi: 10.1016/j.clinthera.2010.05.007. Review.

PMID:
20685493
[PubMed - indexed for MEDLINE]
11.

Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.

Flomenberg N, Comenzo RL, Badel K, Calandra G.

Biol Blood Marrow Transplant. 2010 May;16(5):695-700. doi: 10.1016/j.bbmt.2009.12.538. Epub 2010 Jan 11.

PMID:
20067838
[PubMed - indexed for MEDLINE]
12.

Plerixafor (Mozobil).

[No authors listed]

Med Lett Drugs Ther. 2010 Apr 5;52(1335):27-8. No abstract available.

PMID:
20360661
[PubMed - indexed for MEDLINE]
13.

Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells.

Flomenberg N, DiPersio J, Calandra G.

Acta Haematol. 2005;114(4):198-205. Review.

PMID:
16269859
[PubMed - indexed for MEDLINE]
14.

A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.

Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, DiPersio J.

Biol Blood Marrow Transplant. 2008 Nov;14(11):1253-61. doi: 10.1016/j.bbmt.2008.08.011.

PMID:
18940680
[PubMed - indexed for MEDLINE]
15.

Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.

Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E, Olivieri A.

Biol Blood Marrow Transplant. 2012 Feb;18(2):241-9. doi: 10.1016/j.bbmt.2011.07.014. Epub 2011 Jul 24.

PMID:
21791194
[PubMed - indexed for MEDLINE]
16.

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.

Duarte RF, Shaw BE, Marín P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martínez-Chamorro C, Mateos-Mazón JJ, Ramírez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH.

Bone Marrow Transplant. 2011 Jan;46(1):52-8. doi: 10.1038/bmt.2010.54. Epub 2010 Mar 22.

PMID:
20305700
[PubMed - indexed for MEDLINE]
17.

Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.

Uy GL, Rettig MP, Cashen AF.

Expert Opin Biol Ther. 2008 Nov;8(11):1797-804. doi: 10.1517/14712598.8.11.1797 . Review.

PMID:
18847313
[PubMed - indexed for MEDLINE]
18.

Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.

Varmavuo V, Mäntymaa P, Kuittinen T, Nousiainen T, Jantunen E.

Transfus Apher Sci. 2012 Jun;46(3):257-62. doi: 10.1016/j.transci.2012.03.011. Epub 2012 Mar 31.

PMID:
22465758
[PubMed - indexed for MEDLINE]
19.

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.

Stewart DA, Smith C, MacFarland R, Calandra G.

Biol Blood Marrow Transplant. 2009 Jan;15(1):39-46. doi: 10.1016/j.bbmt.2008.10.018.

PMID:
19135941
[PubMed - indexed for MEDLINE]
20.

Blood graft composition after plerixafor injection in patients with NHL.

Varmavuo V, Mäntymaa P, Nousiainen T, Valonen P, Kuittinen T, Jantunen E.

Eur J Haematol. 2012 Aug;89(2):128-35. doi: 10.1111/j.1600-0609.2012.01794.x. Epub 2012 May 24.

PMID:
22536949
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk